Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
Publication Date: November 18, 2022
Last Updated: January 31, 2023
Chapter 1: Detection and evaluation of HCV in CKD
1.1: Screening patients with chronic kidney disease (CKD) for hepatitis C virus (HCV) infection
We recommend screening all patients for HCV infection at the time of initial evaluation of CKD. (1, C)
314262
We recommend using an immunoassay followed by nucleic acid testing (NAT) if immunoassay is positive. (1, A)
314262
Chapter 2: Treatment of HCV infection in patients with CKD
We recommend that all patients with CKD (G1-G5), on dialysis (G5D), and kidney transplant recipients (G1T-G5T) with HCV be evaluated for direct-acting antiviral (DAA)-based therapy as outlined in Figure 1. (1, A)
314262
We recommend that the choice of specific regimen be based on prior treatment history, drug–drug interactions, GFR, stage of hepatic fibrosis, kidney and liver transplant candidacy, and comorbidities. (1, A)
If pangenotypic regimens are not available, HCV genotype (and subtype) should guide the choice of treatment (Figure 1).
314262
Overview
Title
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease
Authoring Organization
Kidney Disease Improving Global Outcomes
To continue viewing this pocket guide, please purchase it.
My Library
added to your library.
Grading Table
Feedback